Global CNS Therapeutics Market Size study, by Type (Neurodegenerative, Mood Disorders, Schizophrenia, Autism, Depression), by Application (Hospital Use, Clinic Use, Household, Others) and Regional Forecasts 2018-2025

December 2018 | 200 pages | ID: G2DBC5FB493EN
Bizwit Research & Consulting LLP

Abstracts

Global CNS Therapeutics Market to reach USD 130 billion by 2025.

Global CNS Therapeutics Market valued approximately USD 82.3 billion in 2017 is anticipated to grow with a healthy growth rate of more than 5.93% over the forecast period 2018-2025. The major driving factor of global CNS Therapeutics market are rising cases of mental illness and increasing awareness regarding psychiatric disorders. In addition, expanding geriatric population and rising prevalence of lifestyle associated CNS disorders are some other major driving factors which boosting the market. However, one of the major restraining factor of CNS Therapeutics market is several side effects of CNS therapeutics such as weight gain, insomnia, lowered libido, tremors and agitation which hampers the market growth. It refers CNS disorders that effect the structure or function of the brain or spinal cord such as Parkinson’s, disease, epilepsy, Alzheimer disease, anxiety, depression and bipolar disorders. There are many key advantages of CNS therapeutic such as it has the benefit to high concentration in brain, it reduces systematic side effects, large drug distribution volume, it has flexible therapy protocol and it has consistent drug concentration. The major trend of global CNS therapeutics market is increase in adoption of new generation drugs. The regional analysis of Global CNS Therapeutics Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World.

The major market player included in this report are:

• Pfizer
• Janseen Pharmaceuticals
• Allergan
• Lundbeck
• Teva
• Camber Pharmaceuticals
• Zhejiang Haisen Pharmaceuticals
• Jewim Pharmaceuticals
• Cipla
• Merck Sharp & Dohme Corp.
• Eli Lilly
• GlaxoSmithKline
• Novartis
• LUPIN
• ZYDUS PHARMS

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

• Neurodegenerative
• Mood Disorders
• Schizophrenia
• Autism
• Depression

By Application:

• Hospital Use
• Clinic Use
• Household
• Others

By Regions:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• Asia Pacific
• China
• India
• Japan
• Latin America
• Brazil
• Mexico
• Rest of the World

Furthermore, years considered for the study are as follows:

• Historical year – 2015, 2016
• Base year – 2017
• Forecast period – 2018 to 2025

Target Audience of the Global CNS Therapeutics Market in Market Study:

• Key Consulting Companies & Advisors
• Large, medium-sized, and small enterprises
• Venture capitalists
• Value-Added Resellers (VARs)
• Third-party knowledge providers
• Investment bankers
• Investors

Contents

CHAPTER 1. EXECUTIVE SUMMARY

1.1. Market Snapshot
1.2. Key Trends
1.3. Global & Segmental Market Estimates & Forecasts, 2015-2025 (USD Billion)
  1.3.1. CNS Therapeutics Market, by Type, 2015-2025 (USD Billion)
  1.3.2. CNS Therapeutics Market, by Application, 2015-2025 (USD Billion)
  1.3.3. CNS Therapeutics Market, by Region, 2015-2025 (USD Billion)
1.4. Estimation Methodology
1.5. Research Assumption

CHAPTER 2. CNS THERAPEUTICS MARKET DEFINITION AND SCOPE

2.1. Objective of the Study
2.2. Market Definition & Scope
  2.2.1. Industry Evolution
  2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates

CHAPTER 3. CNS THERAPEUTICS MARKET DYNAMICS

3.1. See Saw Analysis
  3.1.1. Market Drivers
  3.1.2. Market Challenges
  3.1.3. Market Opportunities

CHAPTER 4. CNS THERAPEUTICS MARKET INDUSTRY ANALYSIS

4.1. Porter’s 5 Force Model
  4.1.1. Bargaining Power of Buyers
  4.1.2. Bargaining Power of Suppliers
  4.1.3. Threat of New Entrants
  4.1.4. Threat of Substitutes
  4.1.5. Competitive Rivalry
  4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.2. PEST Analysis
  4.2.1. Political Scenario
  4.2.2. Economic Scenario
  4.2.3. Social Scenario
  4.2.4. Technological Scenario
4.3. Value Chain Analysis
  4.3.1. Supplier
  4.3.2. Manufacturers/Service Provider
  4.3.3. Distributors
  4.3.4. End-Users
4.4. Key Buying Criteria
4.5. Regulatory Framework
4.6. Cost Structure Analysis
  4.6.1. Raw Material Cost Analysis
  4.6.2. Manufacturing Cost Analysis
  4.6.3. Labour Cost Analysis
4.7. Investment Vs Adoption Scenario
4.8. Analyst Recommendation & Conclusion

CHAPTER 5. CNS THERAPEUTICS MARKET, BY TYPE

5.1. Market Snapshot
5.2. Market Performance - Potential Model
5.3. Key Market Players
5.4. CNS Therapeutics Market, Sub Segment Analysis
  5.4.1. Neurodegenerative Diseases
    5.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.4.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  5.4.2. Mood Disorders
    5.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.4.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  5.4.3. Schizophrenia
    5.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.4.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  5.4.4. Autism
    5.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.4.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  5.4.5. Depression
    5.4.5.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.4.5.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)

CHAPTER 6. CNS THERAPEUTICS MARKET, BY APPLICATION

6.1. Market Snapshot
6.2. Market Performance - Potential Model
6.3. Key Market Players
6.4. CNS Therapeutics Market, Sub Segment Analysis
  6.4.1. Hospital Use
    6.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.4.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.4.2. Clinic Use
    6.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.4.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.4.3. Household
    6.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.4.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.4.4. Other
    6.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.4.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)

CHAPTER 7. CNS THERAPEUTICS MARKET, BY REGIONAL ANALYSIS

7.1. CNS Therapeutics Market, Regional Market Snapshot (2015-2025)
7.2. North America CNS Therapeutics Market Snapshot
  7.2.1. U.S.
    7.2.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.2.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.2.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.2.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.2.2. Canada
    7.2.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.2.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.2.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.2.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.3. Europe CNS Therapeutics Market Snapshot
  7.3.1. U.K.
    7.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.3.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.3.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.3.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.3.2. Germany
    7.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.3.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.3.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.3.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.3.3. France
    7.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.3.3.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.3.3.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.3.3.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.3.4. Rest of Europe
    7.3.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.3.4.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.3.4.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.3.4.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.4. Asia CNS Therapeutics Market Snapshot
  7.4.1. China
    7.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.4.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.4.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.4.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.4.2. India
    7.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.4.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.4.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.4.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.4.3. Japan
    7.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.4.3.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.4.3.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.4.3.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.4.4. Rest of Asia Pacific
    7.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.4.4.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.4.4.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.4.4.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.5. Latin America CNS Therapeutics Market Snapshot
  7.5.1. Brazil
    7.5.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.5.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.5.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.5.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.5.2. Mexico
    7.5.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.5.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.5.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.5.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
7.6. Rest of The World
  7.6.1. South America
    7.6.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.6.1.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.6.1.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.6.1.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)
  7.6.2. Middle East and Africa
    7.6.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    7.6.2.2. Components breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.6.2.3. Applications breakdown estimates & forecasts, 2015-2025 (USD Billion)
    7.6.2.4. End user breakdown estimates & forecasts, 2015-2025 (USD Billion)

CHAPTER 8. COMPETITIVE INTELLIGENCE

8.1. Company Market Share (Subject to Data Availability)
8.2. Top Market Strategies
8.3. Company Profiles
  8.3.1. Pfizer
    8.3.1.1. Overview
    8.3.1.2. Financial (Subject to Data Availability)
    8.3.1.3. Product Summary
    8.3.1.4. Recent Developments
  8.3.2. Janseen Pharmaceuticals
  8.3.3. Allergan
  8.3.4. Lundbeck
  8.3.5. Teva
  8.3.6. Camber Pharmaceuticals
  8.3.7. Zhejiang Haisen Pharmaceuticals
  8.3.8. Jewim Pharmaceuticals
  8.3.9. Cipla
  8.3.10. Merck Sharp & Dohme Corp.
  8.3.11. Eli Lilly
  8.3.12. GlaxoSmithKline
  8.3.13. Novartis
  8.3.14. LUPIN
  8.3.15. ZYDUS PHARMS

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process
  9.1.1. Data Mining
  9.1.2. Analysis
  9.1.3. Market Estimation
  9.1.4. Validation
  9.1.5. Publishing
  9.1.6. Research Assumption